Skip to content

Trial Summary

TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα and enhances the phagocytosis of cancer cells by macrophages. In preclinical in vivo models, TQB2928 was active against a wide range of solid tumors and hematologic malignancies. This is the first-in-human phase 1 trial of TQB2928 in patients with advanced solid tumors and hematological malignancies.

Acronym:

TQB2928-I-01

ACTRN/NCT /ethics:

NCT04854681

Scientific title:

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TQB2928 Injection in Patients With Advanced Solid Tumors or Hematological Malignancies

Sponsor / Cooperative group:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Advanced, Metastatic or Widespread
Anticipated Start Date2021-08-01
Anticipated End Date2022-07-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Brian Stein
Recruitment StatusNot Yet Recruiting